Company

Centessa Pharmaceuticals Ltd

Headquarters: Cambridge, United Kingdom

Employees: 70

CEO: Dr. Nicholas Morrell M.D., MBBS

NASDAQ: CNTA +1.79%

Market Cap

$988.0 Million

USD as of July 1, 2024

Market Cap History

Centessa Pharmaceuticals Ltd market capitalization over time

Evolution of Centessa Pharmaceuticals Ltd market cap in the past 5 years

Market capitalizations are calculated from the opening stock price at the beginning of each month.

Market Cap History of Centessa Pharmaceuticals Ltd

Detailed Description

Centessa Pharmaceuticals Limited, a pharmaceutical company, develops and delivers life-altering and life-enhancing medicines to patients. Its products pipeline include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase 3 clinical development for the treatment of autosomal dominant polycystic kidney disease; SerpinPC, an activated protein C inhibitor, which is in Phase 2a clinical development for the treatment of hemophilia A and B; Imgatuzumab, an anti-EGFR monoclonal antibody expected to enter a Phase 2 clinical trial for the treatment of cutaneous squamous cell carcinoma, as well as is being considered for the treatment of other solid tumors in the context of combination treatment with immunotherapy; and ZF874, a small molecule chemical chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase 1 clinical development for the treatment of alpha-1-antitrypsin deficiency. The company's preclinical product candidates comprise ZF887 for alpha-1-antitrypsin deficiency; MGX292 for pulmonary arterial hypertension; CBS001 for idiopathic pulmonary fibrosis; CBS004 for systemic sclerosis and lupus; LB1 and LB2 for solid tumors; Oral OX2R Agonist and Intranasal OX2R Agonist for narcolepsy type 1; Dual STAT3/5 Degrader for hematological malignancies; EGFR Ex20 and EGFR-C797S inhibitors for non-small cell lung cancer; and next generation EGFR inhibitors. The company was formerly known as United Medicines Biopharma Limited and changed its name to Centessa Pharmaceuticals Limited in February 2021. Centessa Pharmaceuticals Limited was incorporated in 2020 and is based in Cambridge, the United Kingdom.

Top 1-year algo backtest: +207.50%

$10,000 in July 2023 would now be $30,750 by following this algorithm daily at market close.

Boost your returns with Disfold DeepFinance... Now!

Try Disfold DeepFinance FREE

Stocks & Indices

Centessa Pharmaceuticals Ltd has the following listings and related stock indices.


Stock: NASDAQ: CNTA wb_incandescent

Stock: FSX: 260 wb_incandescent

Details

Headquarters:

The Dorothy Hodgkin Building Babraham

Research Campus Babraham

Cambridge, CB22 3FH

United Kingdom

Phone: 44 73 9178 9784